Johnson & Johnson pulls plug on Medivir-Achillion hep C cocktail to focus on hep B

Citing a crowded market of innovative meds, Janssen has canned work on its hep C cocktail program with partners Medivir and Achillion. The pair were working on the hepatitis C treatment regimen known as JNJ-4178, a combo of three direct acting antivirals: AL-335, Achillion’s odalasvir and the Janssen-Medivir med Olysio (simeprevir). The Big Pharma said that the ongoing phase 2 tests with JNJ-4178 will be completed as planned, “but there will be no additio